CONCORDBIO - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.9
| Stock Code | CONCORDBIO | Market Cap | 12,351 Cr. | Current Price | 1,180 ₹ | High / Low | 2,452 ₹ |
| Stock P/E | 38.4 | Book Value | 174 ₹ | Dividend Yield | 0.91 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,315 ₹ | DMA 200 | 1,530 ₹ |
| Chg in FII Hold | -0.45 % | Chg in DII Hold | 0.03 % | PAT Qtr | 62.9 Cr. | PAT Prev Qtr | 42.6 Cr. |
| RSI | 37.3 | MACD | -53.8 | Volume | 59,934 | Avg Vol 1Wk | 94,777 |
| Low price | 1,100 ₹ | High price | 2,452 ₹ | PEG Ratio | 1.43 | Debt to equity | 0.00 |
| 52w Index | 5.93 % | Qtr Profit Var | -36.3 % | EPS | 30.7 ₹ | Industry PE | 29.1 |
📊 Analysis: CONCORDBIO is trading at 1,180 ₹, well below its 50 DMA (1,315 ₹) and 200 DMA (1,530 ₹), indicating weak technical strength. RSI at 37.3 shows oversold conditions, but MACD (-53.8) signals strong bearish momentum. Current volume (59.9K) is significantly lower than the 1-week average (94.7K), suggesting limited intraday participation. The setup is risky for intraday trading, with potential for sharp downside if support breaks.
💰 Optimal Buy Price: 1,165–1,180 ₹ (only if price stabilizes near support)
📈 Profit-Taking Levels: 1,200–1,215 ₹ (short-term resistance)
⚠️ Stop-Loss: 1,155 ₹ (below immediate support)
⏳ If Already Holding: Exit intraday if price fails to hold above 1,165 ₹ or if RSI drops further below 35. Consider booking profits if price approaches 1,200–1,215 ₹ but volume remains weak. Watch for MACD widening negatively as a clear exit signal.
Positive
- Debt-free balance sheet (Debt-to-equity 0.00).
- Reasonable PEG ratio (1.43) compared to peers.
- EPS of 30.7 ₹ supports long-term valuation.
- ROCE (28.4%) and ROE (21.4%) show decent efficiency.
Limitation
- Trading below both 50 DMA and 200 DMA, showing weak technicals.
- RSI near oversold zone but momentum remains bearish.
- Quarterly profit variation (-36.3%) indicates earnings pressure.
- Volume significantly below average, limiting intraday opportunities.
- FII holding decreased (-0.45%), showing reduced foreign interest.
Company Negative News
- No major external negative news reported, but earnings decline is a concern.
Company Positive News
- PAT improved sequentially (62.9 Cr. vs 42.6 Cr.), showing recovery momentum.
- DII holdings slightly increased (+0.03%), reflecting cautious domestic support.
Industry
- Industry P/E at 29.1 is lower than CONCORDBIO’s P/E (38.4), suggesting relative overvaluation.
- Biopharma sector remains growth-oriented but volatile.
Conclusion
🔎 CONCORDBIO is a weak candidate for intraday trading due to bearish momentum, low volume, and earnings pressure. While oversold RSI may trigger short bounces, risk outweighs reward. Best strategy: Avoid aggressive intraday positions, only consider small scalps near 1,165–1,180 ₹ with strict stop-loss at 1,155 ₹ and quick exits near 1,200–1,215 ₹.